Richard Hoffman joined Incyte in December 2025 as Executive Vice President and General Counsel. In this role, he serves as a key member of the Executive Leadership Team and is responsible for leading the Company’s global legal and compliance functions.

Mr. Hoffman is an accomplished legal and business leader with more than 20 years of experience advising and supporting biopharmaceutical and life science companies. Prior to joining Incyte, he was a Partner in Goodwin’s Life Sciences group, where he counseled a diverse portfolio of emerging and established biopharma organizations, including Anthos Therapeutics, Compass Therapeutics, Deciphera Pharmaceuticals, PepGen and Syntimmune, on corporate governance, strategic transactions, intellectual property and litigation.

Earlier in his career, Mr. Hoffman held senior leadership positions in the biotechnology industry at Hybridon (now Idera Pharmaceuticals) and Avitech. He holds a B.A. from Harvard College, a J.D. from Columbia Law School and an M.B.A. from The Wharton School of the University of Pennsylvania.